195 related articles for article (PubMed ID: 23289017)
1. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer.
Tang X; Li J; Yu B; Su L; Yu Y; Yan M; Liu B; Zhu Z
Int J Biol Sci; 2013; 9(1):55-66. PubMed ID: 23289017
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.
Hao C; Cui Y; Lane J; Jia S; Ji J; Jiang WG
Cells; 2021 Jul; 10(7):. PubMed ID: 34359989
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells.
Yan W; Qian C; Zhao P; Zhang J; Shi L; Qian J; Liu N; Fu Z; Kang C; Pu P; You Y
Neuro Oncol; 2010 Aug; 12(8):765-75. PubMed ID: 20511184
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K.
Liu J; Liu Q; Wan Y; Zhao Z; Yu H; Luo H; Tang Z
Int J Oncol; 2014 Jul; 45(1):282-90. PubMed ID: 24756245
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines.
Chae S; Jun HO; Lee EG; Yang SJ; Lee DC; Jung JK; Park KC; Yeom YI; Kim KW
Int J Oncol; 2009 Dec; 35(6):1409-16. PubMed ID: 19885563
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.
Hahnel A; Wichmann H; Greither T; Kappler M; Würl P; Kotzsch M; Taubert H; Vordermark D; Bache M
BMC Cancer; 2012 Apr; 12():131. PubMed ID: 22471890
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
8. [Expression of osteopontin splice variant and its clinical significance in gastric cancer].
Sun X; Wang L; Hou W; Li Y; Liu L; Zuo W; Yu J
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):427-30. PubMed ID: 26463145
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma.
Liu W; Xu G; Ma J; Jia W; Li J; Chen K; Wang W; Hao C; Wang Y; Wang X
Tohoku J Exp Med; 2011 May; 224(1):29-39. PubMed ID: 21512310
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation.
Rangaswami H; Bulbule A; Kundu GC
Glycoconj J; 2006 May; 23(3-4):221-32. PubMed ID: 16691505
[TBL] [Abstract][Full Text] [Related]
11. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
Chen RX; Xia YH; Xue TC; Ye SL
Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
[TBL] [Abstract][Full Text] [Related]
13. HER2 promotes epithelial-mesenchymal transition through regulating osteopontin in gastric cancer.
Liu Y; Chen L; Jiang D; Luan L; Huang J; Hou Y; Xu C
Pathol Res Pract; 2021 Nov; 227():153643. PubMed ID: 34634565
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis.
Berge G; Pettersen S; Grotterød I; Bettum IJ; Boye K; Mælandsmo GM
Int J Cancer; 2011 Aug; 129(4):780-90. PubMed ID: 20957651
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation.
Song G; Ouyang G; Mao Y; Ming Y; Bao S; Hu T
J Cell Mol Med; 2009 Aug; 13(8B):1706-1718. PubMed ID: 19602039
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
18. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of osteopontin expression in human gastric carcinoma.
Higashiyama M; Ito T; Tanaka E; Shimada Y
Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
